Efficacy and mechanism of Xuefu Zhuyu Decoction on model rats of coronary heart disease with heart blood stasis syndrome based on metabolomics.
10.19540/j.cnki.cjcmm.20230710.702
- Author:
Jing LI
1
;
Zhi-Hua GUO
1
;
Jian-He LIU
2
;
Sen-Jie ZHONG
3
;
Hui-Fang KUANG
4
;
Yang YANG
4
;
Yi LIU
4
;
Qiu-Yan ZHANG
4
Author Information
1. Hunan University of Chinese Medicine Changsha 410208, China Hunan Key Laboratory of Colleges and Universities of Intelligent Traditional Chinese Medicine Diagnosis and Preventive Treatment of Chronic Diseases,Hunan University of Chinese Medicine Changsha 410208, China.
2. the First Affiliated Hospital of Hunan University of Chinese Medicine Changsha 410007, China.
3. the First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou 510405, China.
4. Hunan University of Chinese Medicine Changsha 410208, China.
- Publication Type:Journal Article
- Keywords:
Xuefu Zhuyu Decoction;
coronary heart disease;
heart blood stasis syndrome;
metabolomics
- MeSH:
Rats;
Animals;
Stroke Volume;
Rats, Sprague-Dawley;
Ventricular Function, Left;
Coronary Disease/drug therapy*;
Metabolomics
- From:
China Journal of Chinese Materia Medica
2023;48(20):5623-5631
- CountryChina
- Language:Chinese
-
Abstract:
This study investigated the effects of Xuefu Zhuyu Decoction on myocardial metabolites in a rat model of coronary heart disease with heart blood stasis syndrome and explored the therapeutic mechanism of blood circulation-promoting and blood stasis-removing therapy. SD rats were randomly divided into a sham operation group, a model group, a Xuefu Zhuyu Decoction group(14.04 g·kg~(-1)), and a trimetazidine group(5.4 mg·kg~(-1)). The sham operation group underwent thread insertion without ligation, while the other groups underwent coronary artery left anterior descending branch ligation to induce a model of coronary heart disease with heart blood stasis syndrome. Three days after modeling, drug intervention was performed, and samples were taken after 14 days of intervention. General conditions were observed, and electrocardiogram and cardiac ultrasound indices were measured. Hematoxylin-eosin(HE) staining and Masson staining were used to observe tissue pathological morphology. The enzyme linked immunosorbent assay(ELISA) was used to measure the levels of triglyceride(TG) and total cholesterol(TC) in the serum. Ultra high performance liquid chromatography-quantitative exactive-mass spectrometry(UHPLC-QE-MS) technology was used to screen differential metabolites in myocardial tissue and conduct metabolic pathway enrichment analysis. The results showed that Xuefu Zhuyu Decoction significantly improved the general condition of the model rats, reduced heart rate and ST segment elevation in the electrocardiogram, increased left ventricular ejection fraction(LVEF) and left ventricular fractional shortening(LVFS), and decreased left ventricular internal diameter in diastole(LVIDd) and left ventricular internal diameter in systole(LVIDs). HE staining and Masson staining showed that Xuefu Zhuyu Decoction effectively alleviated myocardial tissue structural disorders, inflammatory cell infiltration, and collagen fiber deposition in the model rats. ELISA results showed that Xuefu Zhuyu Decoction effectively regulated serum TG and TC levels in the model rats. There were significant differences in the metabolic phenotypes of myocardial samples in each group. Fourteen differential metabolites were identified in the Xuefu Zhuyu Decoction group, involving five metabolic pathways, including arginine and proline metabolism, glycerophospholipid metabolism, aminoacyl-tRNA biosynthesis, ether lipid metabolism, and alanine, aspartate, and glutamate metabolism. Xuefu Zhuyu Decoction improved cardiac function and myocardial structural damage in the rat model of coronary heart disease with heart blood stasis syndrome, and its biological mechanism involved the regulation of lipid metabolism, choline metabolism, amino acid metabolism, energy metabolism, and protein synthesis pathways.
